Journal
ATHEROSCLEROSIS
Volume 213, Issue 2, Pages 545-548Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2010.08.061
Keywords
Soluble tumor necrosis factor-like weak inducer of apoptosis; TWEAK; Apoptosis; Cardiomyocyte proliferation; Heart failure; Cardiomyopathy; Prognosis
Funding
- Association for the Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology (Vienna, Austria)
- Ludwig Boltzmann Foundation for Cardiovascular Research (Vienna, Austria)
Ask authors/readers for more resources
Objective: To assess the prognostic value of the pro-apoptotic, but also cell growth-inducing molecule soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in heart failure (HF). Methods: We assayed sTWEAK levels in 351 patients with advanced HF (non-ischemic: 130, ischemic: 221). During a median follow-up of 4.9 years, 195 patients (56%) died. Results: sTWEAK concentrations were associated with extended survival in patients with non-ischemic (P = 0.022), but not with ischemic HF (P = 0.82). The inverse association in non-ischemic HF remained significant in a multivariable Cox regression model (P = 0.025) with a hazard ratio of 0.40 (95% confidence interval: 0.21-0.77) comparing the third to the first tertile (P = 0.007). Conclusion: Low sTWEAK levels independently predict mortality in advanced non-ischemic HF. sTWEAK-induced proliferation of cardiomyocytes may explain its impact on suvival. The different prognostic value of sTWEAK in ischemic and non-ischemic HF may point towards distinct pathogenic pathways determining the course of disease. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available